Cagrilintide is an amylin analogue that helps regulate appetite. In a randomized trial of over 3400 patients who were overweight or obese and had 1 weight related complication, individuals assigned to a combination Cagrilintide and semaglutide together drive record weight loss in global trial Zepbound Outperforms CagriSema in Head to Head Phase III Obesity Trial Tirzepatide vs. Semaglutide: Which Is Better? New Leaf Online What is the pipeline for future medications for obesity? International Journal of Obesity